Pfizer Total Current Liabilities from 2010 to 2024

PFE Stock  USD 26.26  0.26  1.00%   
Pfizer's Total Current Liabilities is increasing over the years with slightly volatile fluctuation. Overall, Total Current Liabilities is expected to go to about 50.2 B this year. Total Current Liabilities is the total amount of liabilities that Pfizer Inc is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
1985-12-31
Previous Quarter
31.1 B
Current Value
47.8 B
Quarterly Volatility
12.2 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.6 B, Interest Expense of 2.5 B or Total Revenue of 39.5 B, as well as many exotic indicators such as Price To Sales Ratio of 4.62, Dividend Yield of 0.0598 or PTB Ratio of 1.73. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
  
This module can also supplement Pfizer's financial leverage analysis and stock options assessment as well as various Pfizer Technical models . Check out the analysis of Pfizer Correlation against competitors.

Latest Pfizer's Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Pfizer Inc over the last few years. Total Current Liabilities is an item on Pfizer balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pfizer Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Pfizer's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Pfizer Total Current Liabilities Regression Statistics

Arithmetic Mean31,430,293,333
Geometric Mean25,737,877,973
Coefficient Of Variation38.40
Mean Deviation8,448,925,333
Median30,427,000,000
Standard Deviation12,069,637,761
Sample Variance145676155.7T
Range49.2B
R-Value0.84
Mean Square Error45353457.4T
R-Squared0.71
Significance0.000079
Slope2,275,546,429
Total Sum of Squares2039466179.5T

Pfizer Total Current Liabilities History

202450.2 B
202347.8 B
202242.1 B
202142.7 B
202025.9 B
201937.3 B
201831.9 B

About Pfizer Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Current Liabilities47.8 B50.2 B

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out the analysis of Pfizer Correlation against competitors.
Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Global Correlations
Find global opportunities by holding instruments from different markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Dividend Share
1.64
Earnings Share
0.37
Revenue Per Share
10.366
Quarterly Revenue Growth
(0.41)
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.